文献速递免疫规划

基孔肯雅病毒E2 B结构域纳米颗粒免疫原在小鼠中引发同型中和抗体

Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.
PubMed 文献 · Vaccine · 2024-10-15

本研究制备了含基孔肯雅病毒(CHIKV)和马亚罗病毒(MAYV)E2 B结构域的纳米颗粒免疫原并评估其免疫原性。CHIKV E2-B纳米颗粒免疫血清与两种病毒E2-B交叉反应,但仅对CHIKV疫苗株181/25有同型中和活性(血清滴度1:512);MAYV E2-B纳米颗粒诱导非中和抗体,血清与两种病毒E2-B交叉反应。结果表明E2-B免疫优势表位被交叉反应但非交叉中和抗体结合。

要点

  • CHIKV E2-B纳米颗粒免疫血清仅对CHIKV疫苗株181/25有同型中和活性,滴度1:512。
  • CHIKV与MAYV E2-B纳米颗粒免疫血清均与两种病毒E2-B交叉反应。
  • MAYV E2-B纳米颗粒诱导的抗体为非中和抗体。

核心结论

  • CHIKV和MAYV E2-B的免疫优势表位被交叉反应但非交叉中和抗体结合,广谱E2-B疫苗需改造免疫优势格局以诱导广谱中和抗体。

研究设计与样本

  • 研究制备并表征了含CHIKV和MAYV E2-B的纳米颗粒免疫原,并在小鼠中评估免疫应答。

主要发现

  • CHIKV E2-B纳米颗粒免疫血清与CHIKV和MAYV E2-B交叉反应,但对CHIKV疫苗株181/25的中和活性为同型(血清滴度1:512)。
  • MAYV E2-B纳米颗粒免疫诱导非中和抗体,血清与CHIKV和MAYV E2-B均交叉反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alphaviruses are enveloped, positive-sense single-stranded RNA viruses that cause severe human and animal illness. Arthritogenic alphaviruses, such as Chikungunya virus (CHIKV) and Mayaro virus (MAYV), are globally distributed, transmitted by mosquitoes, and can cause rheumatic disease characterized by fever, rash, myalgia, and peripheral polyarthralgia that can persist for years post-infection. These infections can also result in more severe clinical manifestations such as hemorrhage, encephalopathy, and mortality. Several potent monoclonal antibodies (mAbs) with broad neutralizing activity have been shown to bind to the E2 B domain (E2-B) of the alphavirus glycoprotein, suggesting that E2-B epitopes are a site of susceptibility for multiple arthritogenic alphaviruses. However, it is unknown whether E2-B alone can elicit a broadly neutralizing humoral response. Here, we generate and characterize nanoparticle-based immunogens containing CHIKV and MAYV E2-B. Immunization with the CHIKV E2-B nanoparticle elicited sera that were cross-reactive toward CHIKV and MAYV E2-B, but had only homotypic neutralizing activity (serum titer of 1:512) against CHIKV vaccine strain 181/25. Furthermore, immunization with MAYV E2-B nanoparticles elicited non-neutralizing antibody, but sera were cross-reactive for both CHIKV and MAYV E2-B. Our findings suggest that the immunodominant epitopes within CHIKV and MAYV E2-B are bound by cross-reactive, but not cross-neutralizing antibody. Therefore, development of broad E2-B based vaccines that induce broadly neutralizing antibody responses will require engineering to alter the immunodominant landscape.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tong K, Hernandez EM, Basore K, et al. Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice. Vaccine. 2024. PMID: 39413488. doi:10.1016/j.vaccine.2024.126405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。